AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18445662 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SSA)
Number of subjects: 89
Study 18445662 — intervention group
Group type: COMPARATOR
Intervention: Surgery (transsphenoidal approach)
Number of subjects: 89
Study 18447916 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tutorial, interactive skills building workshop, decision support protocol, performance feedback, and educational outreach.
Number of subjects: 0
Study 18447916 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study 18447935 — intervention group
Group type: EXPERIMENTAL
Intervention: Good adherence to antipsychotic medication (defined as less than one month without medication)
Number of subjects: 50
Study 18447935 — intervention group
Group type: COMPARATOR
Intervention: Non-adherence to antipsychotic medication
Number of subjects: 50
Study 18447935 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of depot-antipsychotics
Number of subjects: 50
Study 18450881 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn skin and umbilical cord cleansing
Number of subjects: 23662
Study 18450881 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal fever and prematurity
Number of subjects: 23662
Study 18450881 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility delivery, maternal fever, maternal swelling, multiple births
Number of subjects: 23662
Study 18450881 — intervention group
Group type: EXPERIMENTAL
Intervention: Low paternal education, Madeshi ethnicity, primiparity
Number of subjects: 23662
Study 18450881 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal infections, prematurity, multiple births
Number of subjects: 23662
Study 18451319 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) trial at 5 cm H2O
Number of subjects: 80
Study 18451319 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP) trial at 15 cm H2O
Number of subjects: 80
Study 18451319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 6 ml/kg
Number of subjects: 80
Study 18451319 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 12 ml/kg
Number of subjects: 80
Study 18451319 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateau pressure and tidal volume
Number of subjects: 80
Study 18451319 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress to strain ratio (specific lung elastance)
Number of subjects: 80
Study 18452610 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (10 mg/kg monthly)
Number of subjects: 12
Study 18456875 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 T-cell counts remained less than 300/mm(3) throughout the study period
Number of subjects: 39
Study 18456875 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 T-cell counts normalized after an average of 31 months
Number of subjects: 39
Study 18456875 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed an opportunistic infection in follow-up
Number of subjects: 39
Study 18456875 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed AIDS-defining clinical conditions
Number of subjects: 39
Study 18456875 — intervention group
Group type: EXPERIMENTAL
Intervention: Developed autoimmune diseases
Number of subjects: 39
Study 18456875 — intervention group
Group type: EXPERIMENTAL
Intervention: Died from ICL-related opportunistic infections
Number of subjects: 39
Study 18456875 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activation and turnover in CD4 T lymphocytes
Number of subjects: 39
Study 18456875 — intervention group
Group type: EXPERIMENTAL
Intervention: CD8 T lymphocytopenia (< 180/mm(3)) and degree of CD4 T cell activation (HLA-DR expression) at presentation
Number of subjects: 39
Study 18457470 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg
Number of subjects: 490
Study 18457470 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 50 mg
Number of subjects: 490
Study 18457470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 490
Study 18457580 — intervention group
Group type: EXPERIMENTAL
Intervention: VR group - taught to relax using a VR relaxing environment and audio-visual mobile narratives
Number of subjects: 75
Study 18457580 — intervention group
Group type: COMPARATOR
Intervention: Non-VR group - taught to relax using the same relaxing narratives without VR support
Number of subjects: 75
Study 18457580 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL) group - no relaxation training
Number of subjects: 75
Study 18457586 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis-associated delirium group (12 patients)
Number of subjects: 23
Study 18457586 — intervention group
Group type: COMPARATOR
Intervention: Patients without sepsis-associated delirium (4 patients)
Number of subjects: 23
Study 18457586 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated CRP
Number of subjects: 23
Study 18457586 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated S-100beta
Number of subjects: 23
Study 18457586 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated cortisol
Number of subjects: 23
Study 18457586 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with disturbed autoregulation
Number of subjects: 23
Study 18458170 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic parameters of dyssynchrony
Number of subjects: 498
Study 18463354 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m(2) intravenous infusion weekly for 4 weeks)
Number of subjects: 60
Study 18463735 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon plus ribavirin therapy
Number of subjects: 20
Study 18465380 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD-C
Number of subjects: 121
Study 18465380 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD-I
Number of subjects: 121
Study 18465380 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 121
Study 18471323 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone therapy (soy milk containing 47 mg of isoflavonoid per 8 oz serving three times per day for 12 months)
Number of subjects: 20
Study 18471323 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone therapy
Number of subjects: 20
Study 18473686 — intervention group
Group type: COMPARATOR
Intervention: AAV2 CU h-CLN2 vector administered at a total average dose of 2.5 x 10^12 particle units to 12 locations in the CNS.
Number of subjects: 10
Study 18473686 — intervention group
Group type: COMPARATOR
Intervention: AAV2 CU h-CLN2 vector
Number of subjects: 10
Study 18474099 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin and paclitaxel in combination with whole breast hyperthermia
Number of subjects: 44
Study 18477573 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryos derived from oocytes with cytoplasmic abnormalities (vacuolar cytoplasm or central granulation)
Number of subjects: 964
Study 18477573 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 2 embryos derived from oocytes with irregular shape or large perivitelline space
Number of subjects: 964
Study 18477573 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryos derived from oocytes with extracytoplasmic abnormalities
Number of subjects: 964
Study 18477658 — intervention group
Group type: EXPERIMENTAL
Intervention: U-Na measurement in patients not on diuretics
Number of subjects: 86
Study 18477658 — intervention group
Group type: EXPERIMENTAL
Intervention: FE-UA measurement in patients on diuretics
Number of subjects: 86
Study 18477658 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of U-Na and FE-UA
Number of subjects: 86
Study 18477770 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 11
Study 18477770 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 11
Study 18477813 — intervention group
Group type: EXPERIMENTAL
Intervention: BGAThome (web-based Blood Glucose Awareness Training)
Number of subjects: 40
Study 18477813 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 18480204 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive cardiac troponin test (defined as cardiac troponin I level of 1.0 microg per liter or higher or cardiac troponin T level of 0.1 microg per liter or higher)
Number of subjects: 67824
Study 18480204 — intervention group
Group type: COMPARATOR
Intervention: Negative cardiac troponin test
Number of subjects: 67824
Study 18482659 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 *2 carriers
Number of subjects: 797
Study 18482659 — intervention group
Group type: COMPARATOR
Intervention: CYP2C19 wild-type homozygotes
Number of subjects: 797
Study 18482659 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual platelet aggregation >14% at pre-discharge
Number of subjects: 797
Study 18485781 — intervention group
Group type: EXPERIMENTAL
Intervention: Premarin estrogen replacement therapy (ERT)
Number of subjects: 20
Study 18485781 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy, age-matched)
Number of subjects: 20
Study 18487210 — intervention group
Group type: EXPERIMENTAL
Intervention: Current/recent smokers
Number of subjects: 7743
Study 18487210 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 7743
Study 18487210 — intervention group
Group type: EXPERIMENTAL
Intervention: Current/recent smokers (post-discharge)
Number of subjects: 7743
Study 18487210 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (post-discharge)
Number of subjects: 7743
Study 18495536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral JX-594 (10^8 pfu, 3x10^8 pfu, 10^9 pfu, or 3x10^9 pfu) every 3 weeks
Number of subjects: 14
Study 18504251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1 mg/m(2) on days 1, 4, 8, and 11 plus gemcitabine 800 mg/m(2) on days 1 and 8
Number of subjects: 18
Study 18504251 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and gemcitabine combination
Number of subjects: 18
Study 18504323 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based regimen
Number of subjects: 9193
Study 18504323 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol-based regimen
Number of subjects: 9193
Study 18504323 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted means for Cornell product
Number of subjects: 9193
Study 18504323 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted means for Sokolow-Lyon voltage
Number of subjects: 9193
Study 18504323 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of Cornell product left ventricular hypertrophy
Number of subjects: 9193
Study 18504323 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression of left ventricular hypertrophy by Sokolow-Lyon criteria
Number of subjects: 9193
Study 18504334 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPID (resuscitation with actual performance integrated debriefing)
Number of subjects: 123
Study 18504334 — intervention group
Group type: COMPARATOR
Intervention: Control (historical cohort with feedback but without RAPID)
Number of subjects: 123
Study 18504339 — intervention group
Group type: EXPERIMENTAL
Intervention: Gout
Number of subjects: 9105
Study 18504339 — intervention group
Group type: COMPARATOR
Intervention: No gout
Number of subjects: 9105
Study 18507490 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18507817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track palliative care service (immediate referral)
Number of subjects: 52
Study 18507817 — intervention group
Group type: COMPARATOR
Intervention: Standard best practice (12-week wait)
Number of subjects: 52
Study 18507817 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 18507843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 81
Study 18507871 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of influenza vaccine (129 patients)
Number of subjects: 229
Study 18507871 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration of influenza vaccine (100 patients)
Number of subjects: 229
Study 18509084 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous T cells genetically modified by electroporation with a vector plasmid encoding a CD20-specific chimeric T-cell receptor and neomycin resistance gene
Number of subjects: 7
Study 18509084 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose subcutaneous interleukin-2 (IL-2) injections
Number of subjects: 7
Study 18509084 — intervention group
Group type: EXPERIMENTAL
Intervention: T cells produced by limiting dilution methods
Number of subjects: 7
Study 18509175 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ovarian stimulation (COS) with letrozole and gonadotropins
Number of subjects: 215
Study 18509175 — intervention group
Group type: COMPARATOR
Intervention: No fertility-preserving procedure (Control)
Number of subjects: 215
Study 18510963 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-lasting atrial fibrillation (AF) induced and maintained for 15 min
Number of subjects: 35
Study 18511703 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU-acquired paresis (ICUAP)
Number of subjects: 5
Study 18511703 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength
Number of subjects: 5
Study 18511703 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ICUAP)
Number of subjects: 5
Study 18511703 — intervention group
Group type: EXPERIMENTAL
Intervention: ICUAP
Number of subjects: 5
Study 18514203 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma IL-18 levels (274.1 pg/mL) in women who developed CVD
Number of subjects: 506
Study 18514203 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-18 levels at or above the 90th percentile (442 pg/mL)
Number of subjects: 506
Study 18514203 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-18 levels above the 90th percentile
Number of subjects: 506
Study 18514203 — intervention group
Group type: COMPARATOR
Intervention: Baseline plasma IL-18 levels (233.8 pg/mL) in healthy controls
Number of subjects: 506
Study 18515576 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiretinal prostheses with 16 platinum stimulating electrodes (260- or 520-microm diameter)
Number of subjects: 6
Study 18515576 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiretinal prostheses
Number of subjects: 6
Study 18515577 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed, ultrahigh-resolution OCT (hsUHR-OCT) with a 3.4-mm-diameter circle centered on the optic nerve head (ONH)
Number of subjects: 17
Study 18515577 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed, ultrahigh-resolution OCT (hsUHR-OCT) with shifted 3.4-mm circles (horizontal, vertical, diagonal)
Number of subjects: 17
Study 18515577 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed, ultrahigh-resolution OCT (hsUHR-OCT) with a 3.4-mm-diameter circle
Number of subjects: 17
Study 18519811 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (immunotoxin targeting CD25(high) Treg cells)
Number of subjects: 15
Study 18519811 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cells modified with the fowlpox vector rF-CEA(6D)-TRICOM (following Treg-cell depletion)
Number of subjects: 15
Study 18520226 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted cholecystectomy (Da Vinci Robot, Intuitive Surgical)
Number of subjects: 100
Study 18520226 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 100
Study 18520231 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y) radioembolization using glass microspheres
Number of subjects: 42
Study 18520231 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y) radioembolization using resin microspheres
Number of subjects: 42
Study 18520231 — intervention group
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y) radioembolization (both glass and resin)
Number of subjects: 42
Study 18522979 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded estrogen infusion
Number of subjects: 11
Study 18523152 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CTLA4 antibody
Number of subjects: 0
Study 18534024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical myofascial OMT
Number of subjects: 17
Study 18534024 — intervention group
Group type: COMPARATOR
Intervention: Touch-only sham OMT
Number of subjects: 17
Study 18534024 — intervention group
Group type: COMPARATOR
Intervention: No-touch control
Number of subjects: 17
Study 18535255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (surgical treatment)
Number of subjects: 1218
Study 18535255 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy (medical treatment)
Number of subjects: 1218
Study 18535255 — intervention group
Group type: EXPERIMENTAL
Intervention: mBODE change
Number of subjects: 1218
Study 18535255 — intervention group
Group type: EXPERIMENTAL
Intervention: mBODE increase of more than 1 point
Number of subjects: 1218
Study 18540943 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 500 microg every 3 weeks (Q3W)
Number of subjects: 206
Study 18541822 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients with ADHF
Number of subjects: 29862
Study 18541822 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients in the nonischemic subgroup
Number of subjects: 29862
Study 18541822 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients in the ischemic subgroup
Number of subjects: 29862
Study 18541828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein (LDL)
Number of subjects: 5801
Study 18541828 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol
Number of subjects: 5801
Study 18541828 — intervention group
Group type: EXPERIMENTAL
Intervention: Total to high-density lipoprotein cholesterol ratio
Number of subjects: 5801
Study 18541828 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analyses of lipoprotein parameters
Number of subjects: 5801
Study 18544707 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone treatment
Number of subjects: 3548
Study 18544707 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 3548
Study 18544707 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk genotype at HHEX rs1111875
Number of subjects: 3548
Study 18544707 — intervention group
Group type: EXPERIMENTAL
Intervention: LOC387761 risk genotype
Number of subjects: 3548
Study 18544707 — intervention group
Group type: COMPARATOR
Intervention: None of the selected SNPs
Number of subjects: 3548
Study 18545693 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion (3 g, 6 g, 12 g)
Number of subjects: 30
Study 18545693 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion (12 g)
Number of subjects: 30
Study 18545693 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 30
Study 18547438 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CPR plus AECD monitoring (PowerHeart CRM)
Number of subjects: 192
Study 18547438 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR (code team)
Number of subjects: 192
Study 18549175 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 286
Study 18549175 — intervention group
Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 286
Study 18549890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring (IONM)
Number of subjects: 113
Study 18551042 — intervention group
Group type: EXPERIMENTAL
Intervention: CBR3 11G>A variant
Number of subjects: 101
Study 18551042 — intervention group
Group type: EXPERIMENTAL
Intervention: CBR3 730G>A variant
Number of subjects: 101
Study 18553028 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC transplantation (9.6 +/- 2.6 x 10^7 cells) at 20 sites in the ventricular wall via thoracotomy
Number of subjects: 9
Study 18553028 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMC transplantation
Number of subjects: 9
Study 18554762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF), 600 mg/m(2)/dose, twice daily for 24 months.
Number of subjects: 12
Study 18554762 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) treatment for 18.6 +/- 8.0 months, with a final dosage of 381 +/- 241 mg/m(2) twice daily.
Number of subjects: 12
Study 18559166 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER (10.5 mg daily for an average of 167 days)
Number of subjects: 215
Study 18559695 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 6 weeks
Number of subjects: 170
Study 18559695 — intervention group
Group type: COMPARATOR
Intervention: HMGCR full-length transcript
Number of subjects: 170
Study 18559695 — intervention group
Group type: EXPERIMENTAL
Intervention: HMGCR enzyme activity in cells enriched in HMGCRv_1
Number of subjects: 170
Study 18559695 — intervention group
Group type: EXPERIMENTAL
Intervention: Common HMGCR single-nucleotide polymorphism (rs3846662)
Number of subjects: 170
Study 18559696 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (600 mg)
Number of subjects: 26
Study 18559696 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg)
Number of subjects: 26
Study 18559696 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (on high-sodium diet)
Number of subjects: 26
Study 18559696 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (both diets)
Number of subjects: 26
Study 18560516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured islet cell grafts under anti-thymocyte globulin (ATG) induction and tacrolimus plus mycophenolate mofetil (MMF) maintenance immunosuppression
Number of subjects: 21
Study 18560516 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cellular autoimmunity before transplantation
Number of subjects: 21
Study 18560516 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of cellular autoimmunity after transplantation
Number of subjects: 21
Study 18560516 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without pre-existent T-cell autoreactivity
Number of subjects: 21
Study 18560516 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients reactive to both islet autoantigens GAD and IA-2 before transplantation
Number of subjects: 21
Study 18560516 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibody levels and cellular alloreactivity
Number of subjects: 21